18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - Q3 2022 Consolidated. By continuing to use our service, you agree to our use of cookies. T. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. View real-time stock prices and stock quotes for a full financial overview. Stockhouse. was a. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. By continuing to use our service, you agree to our use of cookies. MONTREAL, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. FY2022 revenue. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. sBLA for F8 formulation of tesamorelin submitted to FDA. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. Stockhouse. com. - On track to meet FY2022. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. com uses cookies on this site. - Cash, bonds and money market funds of US$22. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. 35 as of 10:41 a. By continuing to use our service, you agree to our use of cookies. Stockhouse. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 28 $1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. By continuing to use our service, you agree to our use of cookies. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. 11/05/2020 4:15:02 PM. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Their average twelve-month price target is $36. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. We currently market prescription products for people with HIV in the United States. com uses cookies on this site. 06 million, an increase of. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Nov. (TH. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. 36 morning pop. 33 +0. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. 74M. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. NEW YORK, Dec. Stockhouse. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. T. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. MONTREAL, Sept. Cookies are used to offer you a better browsing experience and to analyze our traffic. Jours fériés des marchés. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. com uses cookies on this site. communications@theratech. NCU. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. Thank you. (Theratechnologies, or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal year 2022. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. By continuing to use our service, you agree to our use of cookies. TH | September 26, 2023. Their THTX share price targets range from $36. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. 40%. For investor inquiries: Leah Gibson. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. m. By continuing to use our service, you agree to our use of cookies. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. Theratechnologies Inc. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. . Investor inquiries: Elif McDonald. Marsolais’ presentation will be available through. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. Cookies are used to offer you a better browsing experience and to. We also use them to share usage information with our partners. By continuing to use our service, you agree to our use of cookies. C. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. Theratechnologies Inc. com uses cookies on this site. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. View Company Info for Free. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. Senior Director, Investor Relations. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. US Headquarters. Theratechnologies, Inc. MONTREAL, Aug. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. 71%. Theratechnologies is pepped up on peptides. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. com uses cookies on this site. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Company Type For Profit. By continuing to use our service, you agree to our use of cookies. We also use them to share usage information with our partners. 9 million and US. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. : 001-35203 Mr. com uses cookies on this site. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. . $30. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. com uses cookies on this site. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. 38. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. T. By continuing to use our service, you agree to our use of cookies. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. - Cash, bonds and money market funds of US$22. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . We also use them to share usage. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 75. The price has fallen in 7 of the last 10 days and is down by -30. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. 51 to 200 Employees. -based clinical sites participating in the conduct of the Phase. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our. Theratechnologies to Announce Financial Results for Its First Quarter 2022. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. ( THTX 3. : Nasdaq Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Aug. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. The financial results presented in this press release are taken from the. com. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. com uses cookies on this site. A live webcast of Dr. Unveiling Silvercorp's golden potential at the Ying Mining District. Stockhouse. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. Theratechnologies Announces 1-for-4 Reverse Stock Split. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 617-356-1009. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. MONTREAL, Feb. In the United States, Trogarzo ® (ibalizumab. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. S. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). TH | September 5, 2023. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. By continuing to use our service, you agree to our use of cookies. 63. L. We also use them to share. TH Stock Message Board for Investors. Theratechnologies inc. 04) earnings per share (EPS) for the quarter. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. During the last trading day the stock fluctuated 4. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. The business had revenue of $27. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Nov. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . (THTX) Stock Price, Quote & News - Stock Analysis -20. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. Consensus forecasts updated Jul 21. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. 1-438. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. By continuing to use our service, you agree to our use of cookies. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 00 in the next twelve months. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Stockhouse. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. 68 to a day high of $1. 08). It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Senior Director, Investor Relations. com. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. By Nick Paul Taylor Jul 12, 2023 8:57am. (TH. The abstract and poster can be found on Theratechnologies’ website. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We currently market prescription products for people with HIV in the United States. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 54% and a negative trailing twelve-month return on equity of. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. FAQ – Émetteurs inscrits NOUVEAU. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. S. By continuing to use our service, you agree to our use of cookies. - 2023 Q3 positive adjusted EBITDA to be achieved. Find the latest Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. com uses cookies on this site. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. The company had revenue of $20. MONTREAL, Nov. Statut du système de négociation. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. Montréal, Québec, Canada . By continuing to use our. Theratechnologies Inc. Elif McDonald - Senior Director, Investor Relations. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. During the last trading day the stock fluctuated 12. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Find the latest Theratechnologies Inc. is a pharmaceutical company. com uses cookies on this site. Wainwright NASH Investor Conference. Stockhouse. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. - Issued and outstanding common shares to be consolidated on the basis of 1 post. 23) diluted earnings per. 514-336-7800. By continuing to use our service, you agree to our use of cookies. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. Stockhouse. ET. This suggests a possible upside of 2,471. T. MONTREAL, Oct. We currently market prescription products for people with HIV in the United States. VANCOUVER, British Columbia, Nov. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. By continuing to use our service, you agree to our use of cookies. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. Data presented at AMCP Nexus 2023. com uses cookies on this site. 66% compared to the previous year's 69. View real-time stock prices and stock quotes for a full financial overview. Stockhouse. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Phone Number (514) 336-7800. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. com uses cookies on this site. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. 9 million, adjusted EBITDA of $2. 00. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. 2% per year. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. European Headquarters. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. European Headquarters. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. THTX | Complete Theratechnologies Inc. (THTX) stock. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Jan. 5%. THERATECHNOLOGIES INC. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. Stockhouse. Senior Director, Investor Relations. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. 6. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. A high-level overview of Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Gary Littlejohn. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. is a speaker and consultant of Theratechnologies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. First Quarter Fiscal 2022 Financial Results. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. By continuing to use our service, you agree to our use of cookies. MONTREAL, Oct. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Theratechnologies Inc. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. MONTREAL, Feb. View analysts price targets for THTX. THTX | Complete Theratechnologies Inc. MONTREAL, Oct. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. By continuing to use our service, you agree to our use of cookies. View real-time stock prices and stock quotes for a full financial overview. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Browse posts by Sector and Subsector. Free cash flow. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. We also use them to share usage. com uses cookies on this site. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. We also use them to share usage. Further. . This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. Trogarzo® and.